Equities Analysts Issue Forecasts for Annexon Q1 Earnings

Annexon, Inc. (NASDAQ:ANNX) – Research analysts at HC Wainwright raised their Q1 2026 earnings estimates for Annexon in a report released on Thursday, April 2nd. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($0.31) per share for the quarter, up from their previous forecast of ($0.36). The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.22) EPS, FY2027 earnings at ($0.94) EPS, FY2028 earnings at ($0.55) EPS and FY2029 earnings at ($0.05) EPS.

Several other equities research analysts have also commented on ANNX. Chardan Capital reissued a “buy” rating and set a $16.00 price objective on shares of Annexon in a research note on Friday, March 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Wednesday, January 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Annexon Price Performance

NASDAQ:ANNX opened at $5.99 on Tuesday. Annexon has a one year low of $1.28 and a one year high of $7.18. The company’s 50-day simple moving average is $5.49 and its 200 day simple moving average is $4.67. The firm has a market capitalization of $961.22 million, a P/E ratio of -4.40 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04.

Institutional Trading of Annexon

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANNX. Adage Capital Partners GP L.L.C. increased its holdings in Annexon by 266.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,500,000 shares of the company’s stock valued at $27,610,000 after buying an additional 4,000,000 shares during the last quarter. Mak Capital One LLC purchased a new stake in Annexon during the fourth quarter valued at approximately $14,852,000. State Street Corp increased its holdings in Annexon by 126.9% during the fourth quarter. State Street Corp now owns 4,652,185 shares of the company’s stock valued at $23,354,000 after buying an additional 2,601,877 shares during the last quarter. Nuveen LLC increased its holdings in Annexon by 327.1% during the fourth quarter. Nuveen LLC now owns 2,915,324 shares of the company’s stock valued at $14,635,000 after buying an additional 2,232,766 shares during the last quarter. Finally, BVF Inc. IL increased its holdings in Annexon by 30.4% during the fourth quarter. BVF Inc. IL now owns 9,128,080 shares of the company’s stock valued at $45,823,000 after buying an additional 2,128,080 shares during the last quarter.

Insider Activity

In other news, EVP Ted Yednock sold 7,857 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total transaction of $40,149.27. Following the completion of the transaction, the executive vice president directly owned 97,227 shares of the company’s stock, valued at $496,829.97. The trade was a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jennifer Lew sold 7,851 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total transaction of $40,118.61. Following the transaction, the chief financial officer directly owned 113,765 shares of the company’s stock, valued at $581,339.15. The trade was a 6.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 32,513 shares of company stock valued at $165,973 over the last three months. Corporate insiders own 11.87% of the company’s stock.

Key Stories Impacting Annexon

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright raised quarterly EPS forecasts for Q1–Q4 2026 (each quarter moved roughly from ($0.35)–($0.36) to ~$($0.30)–($0.31)), signaling an improved near‑term operating/profitability outlook. Article Title
• Positive Sentiment: HC Wainwright lifted its FY2026 EPS forecast to ($1.22) from ($1.43) and raised FY2027 to ($0.94) (from ($1.09)), indicating the firm expects losses to shrink meaningfully over the next 1–2 years — a positive signal for investors focused on path to profitability. Article Title
• Positive Sentiment: FY2028 estimates were also improved (raised from ~$($0.62) to ($0.55)), suggesting continued convergence toward break‑even by the end of the decade under HC Wainwright’s model. Article Title
• Neutral Sentiment: HC Wainwright’s FY2026 outlook (-$1.22) still sits below the market consensus cited in the note (current consensus listed as -$0.96), so while the firm improved its own forecasts, ANNX remains forecasted to lose money this year. This limits how much upside multiple compression or re‑rating can occur on the news alone. Article Title
• Negative Sentiment: HC Wainwright trimmed its FY2029 estimate slightly (from ($0.04) to ($0.05)), showing that out‑year uncertainty remains and that the path to profitability is not guaranteed. This is a modest negative for very long‑term forecasts. Article Title

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.